<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce S Bochner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 10, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss) is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis of the small and medium-sized arteries, although the vasculitis is often not apparent in the initial phases of the disease, and approximately 60 percent do not have detectable ANCA [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The most commonly involved organ is the lung, although vasculitis of extrapulmonary organs is largely responsible for the morbidity and mortality associated with EGPA. The goals of therapy are to achieve rapid onset of remission (particularly organ-threatening manifestations), maintain a long remission, and minimize complications of therapy.
        </p>
        <p>
         The treatment and prognosis of EGPA will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of this disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">
          "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ASSESSING VASCULITIS SEVERITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 2021 American College of Rheumatology/Vasculitis Foundation (ACR/VF) guidelines approach initial treatment of EGPA by differentiating patients with severe EGPA that is organ or life-threatening from those with nonsevere disease [
         <a href="#rid1">
          1
         </a>
         ]. Organ or life-threatening features include, but are not limited to, active glomerulonephritis, pulmonary hemorrhage, cerebral vasculitis, progressive peripheral or cranial neuropathy, gastrointestinal bleeding due to vasculitis, pericarditis, or myocarditis.
        </p>
        <p>
         Two other scoring systems are used to assess vasculitis disease activity in patients with EGPA and other vasculitides: the "five-factor score" (FFS) and the Birmingham Vasculitis Activity Score (BVAS). The FFS, while it does not distinguish severe and nonsevere disease for initial EGPA management, may be helpful for identifying patients in need of more aggressive treatment  (
         <a class="graphic graphic_table graphicRef50118" href="/z/d/graphic/50118.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. The BVAS is a research tool that is seldom used in clinical practice [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Five-factor score (FFS)
         </strong>
         – The FFS, initially devised in 1996 [
         <a href="#rid4">
          4
         </a>
         ], was revised in 2011  (
         <a class="graphic graphic_table graphicRef50118" href="/z/d/graphic/50118.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age &gt;65
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiac insufficiency
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gastrointestinal involvement
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Renal insufficiency (stabilized peak plasma creatinine concentration &gt;1.7 mg/dL [150 micromol/L])
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of ear, nose, and throat (ENT) manifestations (presence is associated with a better prognosis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The presence of each factor is given one point. The FFS score ranges from 0 to 2: a score of 0 is given when none of the factors are present, a score of 1 for one factor, and a score of 2 for two or more factors. This scoring system has also been correlated with prognosis. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Birmingham Vasculitis Activity Score (BVAS)
         </strong>
         – The BVAS has largely been applied in clinical research to patients with granulomatosis with polyangiitis and microscopic polyangiitis, but is also used in EGPA [
         <a href="#rid5">
          5,6
         </a>
         ]. The score includes both general symptoms (arthralgia, arthritis, and fever) and involvement of eight major organ systems (skin, mucous membranes, ear/nose/throat, cardiovascular, pulmonary, gastrointestinal, renal, nervous system) [
         <a href="#rid3">
          3
         </a>
         ]. At each site, persistent symptoms or manifestations (eg, sensorineural deafness, pulmonary nodule, alveolar hemorrhage) are given one point and new or worse symptoms are given two points. The score ranges from 0 (complete remission) to a maximum of 68. (See
         <a class="medical medical_review" href="/z/d/html/8224.html" rel="external">
          "Overview of the management of vasculitis in adults", section on 'Monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          REMISSION INDUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary therapy for EGPA is systemic glucocorticoids [
         <a href="#rid1">
          1
         </a>
         ]. An additional immunomodulatory agent is typically added, guided by disease severity and specific organ involvement [
         <a href="#rid1">
          1,7
         </a>
         ]. (See
         <a class="local">
          'Assessing vasculitis severity'
         </a>
         above.)
        </p>
        <p>
         Asthma is additionally managed according to current guidelines, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management", section on 'Initiating pharmacologic treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Adjusting controller therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Systemic glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic glucocorticoid therapy is the mainstay of treatment for EGPA. For adults with evidence of systemic vasculitis, treatment is initiated with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or equivalent) at a dose of 0.5 to 1 mg/kg (up to 80 mg) per day [
         <a href="#rid1">
          1,8
         </a>
         ]. The higher dose is used for patients with more severe vasculitis (eg, impending respiratory failure, cardiac involvement, glomerulonephritis, neuropathy). With acute multiorgan disease, intravenous (IV) glucocorticoid (eg,
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         500 to 1000 mg IV daily for three to five days) is used for initial therapy, followed by oral glucocorticoid therapy as noted [
         <a href="#rid1">
          1,9,10
         </a>
         ].
        </p>
        <p>
         Most patients with EGPA, who do not have poor prognostic factors, achieve a remission with glucocorticoid therapy alone, although relapses are common [
         <a href="#rid11">
          11
         </a>
         ]. In a study of 72 patients without poor prognosis factors (ie, no cardiac, renal, or central nervous system involvement) followed for five years or longer, 93 percent achieved a remission with glucocorticoid therapy alone [
         <a href="#rid11">
          11
         </a>
         ]. However, patients with involvement of the heart, kidney, gastrointestinal tract, or central nervous system usually require additional immunosuppressive therapy as described below. (See
         <a class="local">
          'Glucocorticoid dosing and taper'
         </a>
         below and
         <a class="local">
          'Cyclophosphamide'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4142902787">
         <span class="h2">
          Severe EGPA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe EGPA and organ or life-threatening disease manifestations as defined by the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guidelines (see
         <a class="local">
          'Assessing vasculitis severity'
         </a>
         above), we recommend including
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         <strong>
          or
         </strong>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in the remission induction regimen rather than glucocorticoids alone or glucocorticoids plus
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         , in agreement with the ACR/VF guidelines [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H505711401">
         <span class="h3">
          Choice of agent
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preference for
         </strong>
         <strong>
          cyclophosphamide
         </strong>
         –
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         may be preferred in patients with active cardiac involvement because cardiomyopathy is an independent predictor of mortality in EGPA and experience with cyclophosphamide is more robust in these patients [
         <a href="#rid1">
          1
         </a>
         ]. In addition, cyclophosphamide may be preferred over
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in patients who are antineutrophil cytoplasmic antibody (ANCA)-negative and have severe neurologic or gastrointestinal manifestations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preference for
         </strong>
         <strong>
          rituximab
         </strong>
         –
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         may be preferred in patients with a positive ANCA, active glomerulonephritis, prior
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         therapy, and those at risk for gonadal toxicity [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         is a remission induction agent that is added to systemic glucocorticoids for patients with severe, multi-organ EGPA [
         <a href="#rid1">
          1,4,12-21
         </a>
         ]. The decision to add cyclophosphamide is based on the severity of disease in terms of number of organ systems involved and degree of impairment. A five-factor score (FFS) of 2 or greater  (
         <a class="graphic graphic_table graphicRef50118" href="/z/d/graphic/50118.html" rel="external">
          table 1
         </a>
         ), which correlates with severe disease, is associated with greater mortality among patients who are treated with glucocorticoids alone, compared with those who also receive cyclophosphamide [
         <a href="#rid16">
          16,18
         </a>
         ]. We favor cyclophosphamide in such patients due to the prompt onset of action and improved outcomes with cyclophosphamide. (See
         <a class="local">
          'Assessing vasculitis severity'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         can be administered orally (eg, 1.5 to 2 mg/kg every day for three to six months) or intravenously (eg, 15 mg/kg every two weeks for three doses and then every three weeks for at least three doses) with dose reductions for kidney function and age ≥70 years, as described for granulomatosis with polyangiitis (GPA) [
         <a href="#rid1">
          1,17
         </a>
         ]. Insufficient data are available for EGPA to make a clear recommendation between oral and intravenous therapy. Extrapolating from GPA, outcomes with daily and monthly regimens are similar; a slightly greater risk of bladder toxicity with the daily regimen and a slightly greater risk of relapse with the monthly regimen have been noted. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Cyclophosphamide-based regimen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dosing and monitoring considerations for daily and monthly administration of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         are described separately. Mercaptoethane sulfonate (
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          Mesna
         </a>
         ) is sometimes used to reduce bladder toxicity during infusions of cyclophosphamide, although practices vary among vasculitis centers [
         <a href="#rid1">
          1,9,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The duration of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         therapy remains controversial. When used to treat GPA, typically a six-month regimen is used. In a preliminary study of patients with EGPA, those receiving six pulses of cyclophosphamide had a greater number of mild relapses than those receiving 12 pulses (94 versus 41 percent) [
         <a href="#rid19">
          19
         </a>
         ]. However, we favor six pulses of cyclophosphamide as further data are needed to clarify whether the benefits of 12 pulses of cyclophosphamide outweigh the additional risks. (See
         <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">
          "General toxicity of cyclophosphamide in rheumatic diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Cyclophosphamide-based regimen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in EGPA is supported by the following studies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a meta-analysis of 277 patients with EGPA, microscopic polyangiitis, and polyarteritis and an FFS of 2  (
         <a class="graphic graphic_table graphicRef50118" href="/z/d/graphic/50118.html" rel="external">
          table 1
         </a>
         ), survival was significantly prolonged among patients treated with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and glucocorticoids rather than glucocorticoids alone [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with an FFS of 1, particularly in the presence of cardiac or central nervous system involvement, tend to have a higher mortality than those with an FFS of 0 [
         <a href="#rid4">
          4,17,19
         </a>
         ]  (
         <a class="graphic graphic_table graphicRef50118" href="/z/d/graphic/50118.html" rel="external">
          table 1
         </a>
         ). In a series of patients with an FFS of 1, a lower mortality was noted among those who were treated with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         compared with a separate group in which only some of the patients received cyclophosphamide (7 versus 26 percent mortality, respectively) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2725938574">
         <span class="h3">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         is an anti-CD20 monoclonal antibody directed against B cells that is licensed for the treatment of GPA and microscopic polyangiitis (MPA) in the United States and Europe. Several case reports and case series have described improvement in refractory or relapsing EGPA [
         <a href="#rid22">
          22-35
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adults: 375 mg/m
         <sup>
          2
         </sup>
         IV weekly for four doses or 1000 mg IV on days 1 and 15
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children: 375 mg/m
         <sup>
          2
         </sup>
         IV weekly for four doses or 575 mg/m
         <sup>
          2
         </sup>
         for patients with body surface area ≤1.5m
         <sup>
          2
         </sup>
         or 750 mg/m
         <sup>
          2
         </sup>
         for patients with body surface area &gt;1.5m
         <sup>
          2
         </sup>
         with a typical maximum of 1 g per infusion, administered on days 1 and 15
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Response to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was assessed in a retrospective study of 41 patients seen at four highly specialized vasculitis centers [
         <a href="#rid33">
          33
         </a>
         ]. After the first infusion with rituximab, improvements in disease activity (remission and partial response) were achieved in 83 percent of patients at six months, and at 12 months the improvement rate was nearly 90 percent. Although the
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         dose could be reduced in most patients, only 6 percent of patients were off all treatment with prednisolone by the end of the observation period. Rituximab appeared to cause immediate and severe bronchospasm in two patients with ANCA-negative EGPA [
         <a href="#rid36">
          36
         </a>
         ]. A subsequent study in patients with relapsing EGPA showed that rituximab reduced disease activity and prednisolone requirement, but relapses occurred despite maintenance rituximab [
         <a href="#rid37">
          37
         </a>
         ]. In a single-center retrospective cohort study of 17 patients with EGPA (13 positive for myeloperoxidase antibodies [MPO]) who presented with severe uncontrolled or glucocorticoid-dependent asthma and received rituximab for remission induction, rituximab appeared to be safe and had glucocorticoid-sparing efficacy for asthma control [
         <a href="#rid38">
          38
         </a>
         ]. A small, retrospective study showed improved cardiac function with lower circulating eosinophil numbers after rituximab therapy in ANCA-negative and ANCA-positive EGPA patients with myocardial or endocardial involvement [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">
          "Overview of biologic agents in the rheumatic diseases", section on 'B-cell depletion and inhibition'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A systematic review of observational studies including 368 adults with EGPA showed that the majority of the evaluable EGPA patients treated with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         achieved remission (80 percent partial and complete remission rate). However, heterogeneity among these studies limit interpretation of results, and methodologic differences prevent comparison of rituximab with other biologic agents [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H115420085">
         <span class="h2">
          Nonsevere EGPA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonsevere EGPA is defined as absence of life or organ-threatening manifestations [
         <a href="#rid1">
          1
         </a>
         ]. Patients with nonsevere EGPA often have rhinosinusitis, asthma, eosinophilic pneumonia or transient eosinophilic pulmonary infiltrates, and mild systemic disease (eg, uncomplicated cutaneous) manifestations.
        </p>
        <p class="headingAnchor" id="H1988586241">
         <span class="h3">
          Mepolizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         For adults with nonsevere EGPA, we suggest adding
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         to systemic glucocorticoids rather than
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         in agreement with the ACR/VF guidelines [
         <a href="#rid1">
          1
         </a>
         ]. Other anti-IL-5 agents may also be effective, but supportive evidence is less robust.
        </p>
        <p class="bulletIndent1">
         The use of anti-IL-5 or anti-IL-5 receptor therapy in severe asthma and other conditions such as hypereosinophilic syndrome is described separately. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Anti-IL-5 therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2210.html" rel="external">
          "Hypereosinophilic syndromes: Treatment", section on 'Mepolizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         – The dose of
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         for the treatment of EGPA, advised by the ACR/VF guidelines and approved by the FDA, is 300 mg every four weeks; this dose is higher than the dose of 100 mg every four weeks approved by the FDA for severe asthma [
         <a href="#rid41">
          41
         </a>
         ]. Whether the 300 mg dose is superior to a 100 mg dose for EGPA has not been determined. A multicenter, retrospective analysis of 203 EGPA patients treated with mepolizumab (168 received 100 mg/four weeks; 35 received 300 mg/four weeks) showed comparable efficacy for the control of the systemic and respiratory disease manifestations and a similar low rate of adverse events [
         <a href="#rid42">
          42
         </a>
         ]. Other data suggest that mepolizumab 100 mg every four weeks may be effective in treating severe asthma in many EGPA patients with vasculitis in remission, but a higher dose may be needed for optimal outcomes in some patients [
         <a href="#rid43">
          43,44
         </a>
         ]. The two doses should be compared in the setting of a controlled trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         in patients with EGPA has been assessed in a randomized trial [
         <a href="#rid45">
          45
         </a>
         ] and in case reports [
         <a href="#rid46">
          46-48
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a multicenter trial, 136 patients with relapsing or refractory EGPA were randomly assigned to receive
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         300 mg or placebo, subcutaneously every four weeks for 52 weeks [
         <a href="#rid45">
          45
         </a>
         ]. Mepolizumab led to significantly more accrued weeks of remission (Birmingham Vasculitis Activity Score [BVAS] 0 and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ≤4 mg/day), than placebo (odds ratio [OR] 5.91, 95% CI 2.68-13.03) and a higher percentage of participants in remission at weeks 36 and 48 (OR 16.74, 95% CI 3.61-77.56). Overall, 44 percent of mepolizumab-treated subjects were able to taper
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         or prednisone to 4 mg/day or less, compared with 7 percent of subjects taking placebo. However, 47 percent of participants in the mepolizumab group did not achieve remission.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In 10 patients with refractory or relapsing EGPA (defined by a BVAS of &gt;3),
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         was administered in nine infusions, 750 mg once every four weeks, followed by maintenance therapy with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         and glucocorticoids (tapered dosage to &lt;7.5 mg/day) [
         <a href="#rid46">
          46
         </a>
         ]. Eight patients achieved a BVAS of 0 and a glucocorticoid dose less than 7.5 mg/day. One additional patient achieved a BVAS of 0, but was not able to decrease the glucocorticoid dose below 7.5 mg/day. Another patient achieved a remission, but was subsequently excluded from the study due to nonadherence. After switching to methotrexate, two major and five minor relapses occurred over a median follow-up of 10 months. (See
         <a class="local">
          'Assessing vasculitis severity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          Mepolizumab
         </a>
         was administered monthly for four doses to seven patients with EGPA [
         <a href="#rid47">
          47
         </a>
         ]. The patients who were all on systemic glucocorticoid therapy had a decrease in peripheral eosinophil counts and were able to decrease their
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose by 60 percent. By 20 weeks after discontinuation of mepolizumab, peripheral eosinophils had increased to premepolizumab levels, and asthma exacerbations had necessitated an increase in systemic glucocorticoids almost to the premepolizumab level.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a case report, EGPA, manifest by asthma, mononeuritis multiplex, and pulmonary opacities with 60 percent eosinophils on bronchoalveolar lavage, was refractory to high-dose
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , but responded to intravenous administration of
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         (750 mg/month) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1437875719">
         <span class="h3">
          Methotrexate, azathioprine, mycophenolate as alternative agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alternative induction regimens for patients with nonsevere EGPA (eg, FFS of 1, but mild nonorgan-threatening disease) include initial treatment with glucocorticoids plus
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         [
         <a href="#rid1">
          1,49,50
         </a>
         ]. These agents are preferred over
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in patients with nonsevere EGPA because of lower toxicity [
         <a href="#rid1">
          1
         </a>
         ], but have not been compared directly with
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         .
        </p>
        <p>
         The use of an alternative induction regimen was evaluated in a study of 100 patients with early systemic ANCA-positive vasculitides (including EGPA) that compared glucocorticoids plus
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         with glucocorticoids plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid49">
          49
         </a>
         ]. The remission success rate was similar at six months (90 and 94 percent, respectively). However, the methotrexate regimen was less successful for patients with more extensive disease or pulmonary involvement. (See
         <a class="local">
          'Methotrexate'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Methotrexate
         </strong>
         –
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         is typically initiated at a dose of 15 mg/week orally or subcutaneously, with increases in dose every two to eight weeks of 5 mg/week up to 25 mg/week, as described for granulomatosis with polyangiitis. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of methotrexate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Azathioprine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         is typically initiated at a dose of 50 mg/day if thiopurine methyltransferase (TPMT) testing has not been performed prior to initiation of therapy. If this dose is tolerated well at one week, the daily dose can be increased over several weeks to 2 mg/kg per day. If TPMT testing is performed prior to the initiation of therapy and is normal, azathioprine can be initiated at 2 mg/kg per day; the maximum dose should generally not exceed 200 mg/day. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of azathioprine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycophenolate
         </strong>
         – The ACR/VF guidelines include
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         as an alternative induction agent, but data in EGPA are limited [
         <a href="#rid1">
          1
         </a>
         ]. Dosing of mycophenolate mofetil in EGPA would follow recommendations for GPA with a dose of 750 to 1500 mg orally twice daily (total 1.5 to 3 g daily). Details of dosing are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of mycophenolate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          REMISSION MAINTENANCE
         </span>
        </p>
        <p class="headingAnchor" id="H1314061302">
         <span class="h2">
          Glucocorticoid dosing and taper
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once disease manifestations have come under control, the glucocorticoid dose is gradually tapered over variable time periods ranging from 3 to 18 months, as tolerated. A portion of patients will need long-term low-dose oral glucocorticoid therapy (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         10 mg/day or less). In the study of 72 patients described above (see
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         above), almost 80 percent of those who achieved a remission required long-term low-dose glucocorticoid therapy, mainly to control respiratory disease [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         For patients whose initial induction therapy was systemic glucocorticoids alone, but persistent disease manifestations have not allowed tapering below a moderate to high dose (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         more than 10 mg daily), an immunosuppressive agent is often added for a glucocorticoid-sparing effect. The data in support of this come from case series and extrapolation from the management of granulomatosis with polyangiitis [
         <a href="#rid20">
          20,21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Maintenance therapy'
         </a>
         .)
        </p>
        <p>
         In EGPA, late relapses of systemic vasculitis after a successful response to treatment are uncommon [
         <a href="#rid51">
          51
         </a>
         ]. However, premature withdrawal of treatment can result in recurrence.
        </p>
        <p>
         Prevention of complications due to chronic systemic glucocorticoid therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2924739845">
         <span class="h2">
          Choice of maintenance agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         After remission induction (approximately 6 to 12 months), patients are transitioned to a maintenance regimen. The agents employed for maintenance of remission depend in part on the agents that were used for remission induction and response to induction therapy; our approach aligns with that of the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guidelines [
         <a href="#rid1">
          1
         </a>
         ]. Maintenance immunosuppressive therapy is typically continued for 12 to 18 months. Longer-term or indefinite maintenance therapy may be warranted in patients with multiple relapses.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with severe EGPA who received
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         for remission induction, we suggest maintenance therapy with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil rather than
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid52">
          52,53
         </a>
         ]. The maintenance agent is initiated two to four weeks after the last dose of cyclophosphamide. No comparator studies have been done that help guide the selection of a specific agent. Rituximab has not been studied for remission maintenance in EGPA. (See
         <a class="local">
          'Azathioprine'
         </a>
         below and
         <a class="local">
          'Methotrexate'
         </a>
         below and
         <a class="local">
          'Mycophenolate mofetil'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with severe EGPA who achieved remission with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , it is reasonable to continue rituximab [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Rituximab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonsevere disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with nonsevere EGPA who received
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         for remission induction, we suggest continuing mepolizumab and tapering
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or equivalent) as tolerated. (See
         <a class="local">
          'Mepolizumab and other anti-IL-5 agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with nonsevere EGPA who achieved remission with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , we suggest continuation of that agent [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Azathioprine
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with EGPA,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (AZA) is typically used after induction of remission with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or as a glucocorticoid-sparing agent in patients requiring long-term treatment with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at doses greater than 15 mg per day [
         <a href="#rid11">
          11,54
         </a>
         ]. Analysis of the thiopurine methyltransferase (
         <em>
          TPMT
         </em>
         ) gene prior to the administration of AZA may help predict those individuals at risk for severe toxicity. When deficiency of the TPMT enzyme is found, we choose an alternate immunosuppressive agent, such as
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , although data regarding the use of these agents are limited. (See
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Pharmacogenetics and azathioprine toxicity'
         </a>
         .)
        </p>
        <p>
         Different regimens have been reported for initiation of AZA: starting with the target dose of 2 mg/kg lean body weight versus starting at 25 to 50 mg/day for the first week to test for drug hypersensitivity and then increasing by 0.5 mg/kg per day every four to six weeks up to the target dose. In general, we favor going directly to the target dose in order to avoid a relapse during the time that the patient is on suboptimal doses. The direct approach was used successfully in a trial of patients with granulomatosis with polyangiitis [
         <a href="#rid55">
          55
         </a>
         ]. A lower target dose is indicated in patients with renal insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Maintenance therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Dose titration and monitoring'
         </a>
         .)
        </p>
        <p>
         Following the pattern established for granulomatosis with polyangiitis, the timing of initiation of maintenance AZA is based on whether the patient was on daily or monthly dosing of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . For patients on daily dosing, the switch is immediate; for those on monthly dosing, AZA is begun approximately two weeks after the last dose of cyclophosphamide. This is delayed further if the white blood cell count is below 4000 cells/microL, or the absolute neutrophil count is below 1500 cells/microL. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Maintenance therapy'
         </a>
         .)
        </p>
        <p>
         Data in support of a role for
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         in the treatment of EGPA are limited. An open label trial evaluated azathioprine in 10 patients after treatment failure with glucocorticoids alone; five subsequently achieved remission [
         <a href="#rid11">
          11
         </a>
         ]. A small trial that included 51 patients with EGPA with nonsevere disease and a five-factor score (FFS) of 0  (
         <a class="graphic graphic_table graphicRef50118" href="/z/d/graphic/50118.html" rel="external">
          table 1
         </a>
         ) evaluated the addition of azathioprine or placebo to standard daily glucocorticoid therapy [
         <a href="#rid52">
          52
         </a>
         ]. Among patients with EGPA, approximately 52 percent had sustained remission at 24 months, but no difference was noted between azathioprine and placebo groups in rates of attaining remission, risk of relapse, or cumulative dose of glucocorticoids over 24 months.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Methotrexate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         is sometimes used in EGPA to maintain a remission after induction with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or as a glucocorticoid-sparing agent. However,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         may be preferred over methotrexate because it is difficult to monitor for methotrexate pneumonitis in a patient with other causes of dyspnea, such as asthma and pulmonary eosinophilia.
        </p>
        <p>
         Data regarding the use of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         for maintenance of remission in EGPA are limited. In a case series of 25 patients with EGPA, methotrexate was associated with relapse rate of 48 percent, when used for maintenance [
         <a href="#rid56">
          56
         </a>
         ]. On the other hand, the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose was decreased by an average of 50 percent in these patients.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         is occasionally used as an alternative to
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         to induce a remission in patients with an FFS of 1 and mild disease. (See
         <a class="local">
          'Methotrexate, azathioprine, mycophenolate as alternative agents'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         – The dosing regimen for
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         comes from the larger experience using this medication in patients with granulomatosis with polyangiitis (GPA). Methotrexate is typically initiated at a dose of 15 mg/week orally with increases in dose of 5 mg/week every two to eight weeks up to 25 mg/week, if tolerated. Most patients prefer oral over parenteral therapy, although gastrointestinal toxicities may be reduced by weekly subcutaneous administration. Patients are also treated with daily
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         1 mg/day or
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         (2.5 to 5 mg) once per week given 24 hours after methotrexate. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Maintenance therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">
          "Major side effects of low-dose methotrexate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         should be avoided in patients with an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         and is contraindicated during pregnancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1206607408">
         <span class="h2">
          Mycophenolate mofetil
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ACR/VF guidelines view
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         as an acceptable agent for remission maintenance in EGPA based on experience with GPA and case reports of success in EGPA [
         <a href="#rid1">
          1
         </a>
         ]. A few case reports have described successful use of mycophenolate mofetil in EGPA [
         <a href="#rid21">
          21,57-60
         </a>
         ]. In one case report, mycophenolate mofetil plus oral glucocorticoids was used to treat a patient with EGPA manifest by asthma, chronic rhinosinusitis, cutaneous vasculitis, and a positive ANCA (pANCA with antibodies to myeloperoxidase [MPO]) [
         <a href="#rid57">
          57
         </a>
         ]. Dosing and potential side effects of mycophenolate are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1409426116">
         <span class="h2">
          Mepolizumab and other anti-IL-5 agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preparations of anti-interleukin (IL)-5 monoclonal antibodies (
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">
          reslizumab
         </a>
         ) and an anti-IL-5 receptor antibody (
         <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">
          benralizumab
         </a>
         ) are approved for use in severe asthma, and accumulating evidence supports a role in EGPA.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mepolizumab
         </strong>
         – For patients who have achieved remission with
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         and systemic glucocorticoids, we suggest continuing mepolizumab. Long-term maintenance therapy for EGPA with mepolizumab has not been formally examined.
        </p>
        <p>
        </p>
        <p>
         Preliminary evidence suggests that
         <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">
          reslizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">
          benralizumab
         </a>
         may also be of benefit in EGPA:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reslizumab
         </strong>
         – In a cohort of nine EGPA patients with severe eosinophilic asthma requiring continuous glucocorticoids to maintain disease control, 48 weeks of treatment with intravenous
         <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">
          reslizumab
         </a>
         (3 mg/kg every four weeks) was associated with a reduction in glucocorticoid use and improvements in patient-reported outcomes [
         <a href="#rid61">
          61
         </a>
         ]. An open-label study of the safety and efficacy of intravenous reslizumab (3 mg/kg) in 10 subjects found it to be generally safe and effective as treatment for EGPA [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Reslizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benralizumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">
          Benralizumab
         </a>
         , a fully humanized monoclonal antibody that binds with high affinity to the alpha-chain of the interleukin-5 receptor and mediates antibody-dependent eosinophil depletion, reduced glucocorticoid intake and improved clinical manifestations and patient-reported outcomes in patients with EGPA [
         <a href="#rid63">
          63-65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Benralizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         A clinical trial is in progress to compare
         <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">
          benralizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         in EGPA (clinicaltrials.gov NCT04157348).
        </p>
        <p class="headingAnchor" id="H3007858412">
         <span class="h2">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         used for remission maintenance is 500 to 1000 mg IV every four to six months in adults and 250 mg/m
         <sup>
          2
         </sup>
         IV every six months in children [
         <a href="#rid1">
          1
         </a>
         ]. For remission maintenance in GPA and MPA, the ACR/VF guidelines advise redosing based on a schedule rather than based on ANCA levels; this may be extrapolated to EGPA.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Adjunctive topical therapy for asthma and chronic rhinosinusitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjunctive therapies, such as inhaled glucocorticoids, long-acting bronchodilators, and leukotriene modifying agents, are typically used to help control upper and lower respiratory tract disease, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management", section on 'Initiating pharmacologic treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Adjusting controller therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">
          "Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Intranasal corticosteroids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          LESS COMMON THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second-line treatment options may be considered when patients have disease refractory to the above-described conventional therapy or have therapy-limiting side effects. The data in support of these agents are limited to case reports and case series.
        </p>
        <p class="headingAnchor" id="H1552185352">
         <span class="h2">
          Leflunomide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          Leflunomide
         </a>
         , an inhibitor of pyrimidine synthesis, is considered an alternate agent for remission maintenance in EGPA after induction with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or as a glucocorticoid-sparing agent [
         <a href="#rid1">
          1,20
         </a>
         ]. The American College of Rheumatology/Vasculitis Foundation (ACR/VF) guidelines prefer
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         over leflunomide for remission maintenance as data in support of leflunomide for EGPA are limited [
         <a href="#rid1">
          1
         </a>
         ]. The dose of leflunomide used in one case series was 10 to 30 mg/day [
         <a href="#rid20">
          20
         </a>
         ]. This is within the range of dosing used to treat rheumatoid arthritis where there is a greater experience. The dosing and adverse effects of leflunomide in patients with rheumatoid arthritis are described separately. (See
         <a class="medical medical_review" href="/z/d/html/7515.html" rel="external">
          "Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Anti-IgE therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several observational reports have described a beneficial effect of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         (anti-IgE) on certain manifestations of EGPA, such as asthma and sinonasal disease. While omalizumab may have an indirect apoptotic effect on eosinophils, it would not be expected to impact vasculitis. Further studies of safety and efficacy are needed before this approach can be recommended for routine treatment of EGPA. (See
         <a class="medical medical_review" href="/z/d/html/545.html" rel="external">
          "Anti-IgE therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective series of 17 patients with steroid-dependent asthma and refractory or relapsing EGPA,
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         was associated with a decrease in
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dosage to ≤7.5 mg/day without asthma or sinonasal exacerbation in six (35 percent), prednisone dose &gt;7.5 mg/day but no asthma or sinonasal exacerbations in five (30 percent), and no improvement in six (35 percent) [
         <a href="#rid66">
          66
         </a>
         ]. Approximately half of the patients received another immunosuppressive agent in addition to prednisone. Prednisone doses were able to be tapered from a mean of 16 mg/day to 10 mg/day after three months and continued at this level for the 12 months of the study. Mean eosinophil counts did not decrease during omalizumab therapy in this study. While omalizumab may have a steroid-sparing effect, reducing the prednisone dose was associated with disease flares in some patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A case report described a patient with EGPA and nonallergic asthma, whose asthma was refractory to systemic and inhaled glucocorticoid and long-acting beta agonists; asthma control improved with anti-IgE (
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         ) therapy [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another report described improvement in asthma control and a reduction in eosinophil counts with anti-IgE in two patients whose EGPA was not controlled by systemic glucocorticoid [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An observational study of five patients showed that during the 36 months of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         treatment asthma progressively improved and the eosinophilia decreased. The oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose was reduced or withdrawn during treatment [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Conversely, a temporal association between
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         use and the development of EGPA has been reported, although sometimes in the context of tapering of systemic glucocorticoids [
         <a href="#rid70">
          70-72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3371163138">
         <span class="h2">
          Hydroxyurea
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         , an agent that is used in the treatment of the hypereosinophilic syndrome, was found to be beneficial as a glucocorticoid-sparing agent in a patient with EGPA [
         <a href="#rid73">
          73
         </a>
         ]. Hydroxyurea has relatively few side effects compared with other chemotherapeutic agents, although hematological toxicity and gastrointestinal side effects may occur at higher doses. (See
         <a class="medical medical_review" href="/z/d/html/2210.html" rel="external">
          "Hypereosinophilic syndromes: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1713300526">
         <span class="h2">
          Interferon-alpha
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several patients with disease unresponsive to glucocorticoids and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         have improved with a regimen of glucocorticoids and interferon-alpha [
         <a href="#rid6">
          6,54
         </a>
         ]. However, high rates of adverse effects and relapses limit utility of this agent for EGPA. In a retrospective series of 30 patients with EGPA and a medium Birmingham Vasculitis Activity Score (BVAS) of 6 at baseline, interferon-alpha was added to ongoing
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (mean dose 17.5 mg/day) [
         <a href="#rid74">
          74
         </a>
         ]. After initiation of interferon-alpha, the mean prednisolone dose was decreased to 5.5 mg/day. By six months, 16 patients (53 percent) achieved remission, while nine (30 percent) had a partial response. However, only nine patients (36 percent) experienced a sustained remission at a median follow-up of 31 months; 16 patients experienced relapses and 13 experienced major adverse events requiring treatment discontinuation.
        </p>
        <p>
         Interferon-alpha has also been used as a second-line agent for certain patients with the hypereosinophilic syndrome, although discontinuation for adverse effects is common (50 percent). (See
         <a class="medical medical_review" href="/z/d/html/2210.html" rel="external">
          "Hypereosinophilic syndromes: Treatment", section on 'Interferon alfa'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H781077747">
         <span class="h2">
          Intravenous immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several case series have reported improvement in disease control in patients with refractory disease after addition of high-dose intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         to glucocorticoids with or without
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid5">
          5,75,76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Plasma exchange
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma exchange occasionally has been used in conjunction with other therapies, but a meta-analysis involving 140 patients with glomerulonephritis due to EGPA or microscopic polyangiitis found that it added no benefit to treatment with glucocorticoids, with or without
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid77">
          77
         </a>
         ]. It should only be considered for patients with EGPA presenting with rapidly progressive glomerulonephritis or diffuse alveolar hemorrhage [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monitoring responsiveness to treatment and the development of recurrence is best achieved by following symptoms, the eosinophil count, spirometry, and any previously abnormal laboratory parameters. Radiographic manifestations may remain stable or may rapidly regress with glucocorticoid treatment. Kidney function should be monitored by urinalysis and measurement of serum creatinine. We typically reassess patients at three-month intervals, sooner if they experience any change in clinical status.
        </p>
        <p>
         Persistence of antineutrophil cytoplasmic antibody (ANCA) positivity in EGPA may be a marker of an underlying disease process but does not appear to adequately reflect disease activity and, thus, cannot be used by itself to determine changes in therapy [
         <a href="#rid78">
          78,79
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3040.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease", section on 'Monitoring for relapse'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3678363700">
         <span class="h1">
          INFECTION PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should receive age-appropriate vaccination against Pneumococcus, influenza, and SARS-CoV-2 (Coronavirus disease 2019 caused by SARS-CoV-2 virus). (See
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">
          "Pneumococcal vaccination in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines"
         </a>
         .)
        </p>
        <p>
         We suggest
         <em>
          Pneumocystis
         </em>
         prophylaxis for patients who are on a combination of high-dose glucocorticoid (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         20 mg/day or more) and another immunosuppressive agent. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Upper airway involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nasal and otologic complications of EGPA typically require intranasal glucocorticoids and intermittent courses of antibiotics and systemic glucocorticoids [
         <a href="#rid80">
          80,81
         </a>
         ]. Some patients will also require more long-term systemic glucocorticoid therapy and sometimes also immunosuppressive therapy. In addition, surgical approaches, such as functional endoscopic sinus surgery for nasal polypectomy or myringotomy with ventilation tube placement for refractory otitis, may be necessary. When possible, we try to manage the upper airway complications of EGPA with local therapy (
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         lavage and topical glucocorticoids), intermittent courses of systemic glucocorticoids, and addition of
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         for persistent nasal obstruction due to nasal polyposis, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">
          "Chronic rhinosinusitis with nasal polyposis: Management and prognosis"
         </a>
         .)
        </p>
        <p>
         The role of leukotriene modifying agents (LTMA) in the management of asthma and nasal polyposis in patients with EGPA is unclear, due to the reports of EGPA developing in the context of LTMA therapy. In patients with asthma, nasal polyposis, and EGPA who have not previously taken an LTMA, we often add an LTMA to the regimen, as described for patients with aspirin-exacerbated respiratory disease. (See
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Association with medications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/520.html" rel="external">
          "Aspirin-exacerbated respiratory disease", section on 'Leukotriene-modifying agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         EGPA is rare during the child-bearing years, so little is known about the effect of pregnancy on the course of EGPA or the effect of EGPA on gestation. The fetal death rate may be slightly increased among pregnancies occurring in patients with EGPA. As an example, one review reported a fetal death rate of approximately 15 percent among 22 pregnancies [
         <a href="#rid9">
          9
         </a>
         ]. A separate review of 16 pregnancies in patients with EGPA noted vasculitic flares (eg, radiographic opacities, sinusitis, or neuropathy) in four pregnancies (25 percent), one maternal death, and five fetal deaths (one due to maternal death, one spontaneous abortion, one intrauterine death, and two elective terminations of pregnancy) [
         <a href="#rid82">
          82
         </a>
         ]. The effect of EGPA on the placenta is not known.
        </p>
        <p>
         Treatment of vasculitis during pregnancy is complicated due to adverse fetal effects of immunosuppressive medications. As examples,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         are teratogenic and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         is an abortifacient. Systemic glucocorticoids are relatively safer, but may not control active vasculitis. Approaches to the treatment of vasculitis and the use of biologic agents for asthma during pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Pregnant patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/554.html" rel="external">
          "Management of asthma during pregnancy", section on 'Anti-immunoglobulin E'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/554.html" rel="external">
          "Management of asthma during pregnancy", section on 'Anti-interleukin 5'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of patients with EGPA has improved significantly since the widespread use of systemic glucocorticoids and selected use of immunosuppressant agents for patients with more severe disease [
         <a href="#rid20">
          20,21,53,83
         </a>
         ]. Prior to the use of glucocorticoids, for example, the disease was uniformly fatal, with 50 percent of untreated patients dying within three months of the onset of vasculitis. In comparison, most modern clinical series suggest a much improved survival rate (70 to 90 percent at five years) [
         <a href="#rid20">
          20,21,84-86
         </a>
         ].
        </p>
        <p>
         Most deaths result from complications of the vasculitic phase of the disease, and are most commonly due to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac failure and/or myocardial infarction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral hemorrhage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Status asthmaticus
        </p>
        <p>
        </p>
        <p>
         The presence or absence of the features that make up the five-factor score (FFS) has been used to predict survival in EGPA  (
         <a class="graphic graphic_table graphicRef50118" href="/z/d/graphic/50118.html" rel="external">
          table 1
         </a>
         ), although the components of the FFS have changed over the years [
         <a href="#rid4">
          4,18
         </a>
         ]. In the 1990s, an FFS of ≥1 was associated with 25 to 45 percent mortality at five years [
         <a href="#rid4">
          4
         </a>
         ]. Subsequently, survival has improved. One case series followed 118 patients for six years and found a mortality of 14 percent among 44 patients with an FFS ≥1 and an overall mortality of 10 percent [
         <a href="#rid21">
          21
         </a>
         ]. In a separate series, 150 patients with EGPA (of whom 71 percent had received
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) had a 10-year estimated mortality of 11 percent [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Of the five factors, cardiac involvement, gastrointestinal disease, and age ≥65 appear to be the strongest indicators of poor prognosis [
         <a href="#rid20">
          20,21,84
         </a>
         ]. In the case series of 118 patients noted above, an age ≥65 years was the only factor associated with a significantly higher risk of death on multivariate analysis [
         <a href="#rid2">
          2,21
         </a>
         ]. The role of serial antineutrophil cytoplasmic antibody (ANCA) measurements in predicting outcome is not known. However, patients with baseline positive anti-myeloperoxidase (MPO) ANCA had a higher risk of relapse compared with anti-MPO negativity [
         <a href="#rid21">
          21,87,88
         </a>
         ]. The duration of disease-free survival was significantly longer for patients with negative anti-MPO ANCA at entry, although overall survival was not different [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Heart involvement is a leading cause of EGPA-associated deaths [
         <a href="#rid20">
          20
         </a>
         ]; consequently, the possibility of heart transplantation has been considered. A case series showed that heart transplantation is feasible in EGPA, but patients have a poor outcome and more data are needed to improve patient care in this setting [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">
          "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Cardiovascular'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3486570754">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">
          "Society guideline links: Vasculitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of therapy
         </strong>
         – The goals of therapy for eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss) are to achieve rapid onset of remission, followed by a long remission without relapse, and to minimize complications of therapy. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of vasculitis severity
         </strong>
         – Initial therapy is selected based on disease severity, so the first step is determining whether the patient has severe EGPA, defined as organ or life-threatening disease, or nonsevere EGPA. Organ or life-threatening features include, but are not limited to, active glomerulonephritis, pulmonary hemorrhage, cerebral vasculitis, progressive peripheral or cranial neuropathy, gastrointestinal bleeding due to vasculitis, pericarditis, or myocarditis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The five-factor score (FFS) is no longer used for initial determination of disease severity, but can help identify patients in need of more aggressive treatment  (
         <a class="graphic graphic_table graphicRef50118" href="/z/d/graphic/50118.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Assessing vasculitis severity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Remission induction
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Glucocorticoids are a key component of treatment for EGPA; typical initial doses are the equivalent of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.5 to 1 mg/kg (up to 80 mg) per day. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with severe EGPA (organ or life-threatening disease), we recommend remission induction with a combination of systemic glucocorticoids
         <strong>
          and
         </strong>
         either
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , rather than glucocorticoids alone or combined with
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Severe EGPA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with severe EGPA and cardiac or central nervous system involvement, we typically select
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . In contrast, for patients with severe EGPA who have previously received cyclophosphamide or are at risk of gonadal toxicity, we select rituximab. (See
         <a class="local">
          'Choice of agent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with nonsevere EGPA, we suggest remission induction with a combination of systemic glucocorticoids and
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         rather than glucocorticoids alone or induction regimens containing
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). The usual dose of mepolizumab for EGPA is 300 mg subcutaneously every four weeks. An alternative would be to add
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , although the evidence in favor of these agents is less robust.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Remission maintenance
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who received
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         for induction, we recommend a transition to maintenance therapy with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         to sustain the remission, rather than transitioning to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). While experience with mycophenolate in EGPA is limited, it is considered an acceptable alternative based on its use in other antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. (See
         <a class="local">
          'Remission maintenance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who received
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         for induction, we suggest continuing rituximab, rather than switching to another agent, and redosing every four to six months (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Rituximab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who achieved remission with
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         , we suggest continuing mepolizumab, rather than switching to an immunosuppressive agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Mepolizumab has demonstrated benefits in controlling severe asthma, although long-term studies in EGPA are lacking. (See
         <a class="local">
          'Mepolizumab and other anti-IL-5 agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The glucocorticoid dose is gradually tapered to the lowest dose required for control of symptoms and signs of active EGPA. (See
         <a class="local">
          'Glucocorticoid dosing and taper'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maintenance immunosuppressive therapy is typically continued for 12 to 18 months. Longer-term or indefinite maintenance therapy may be warranted in patients with multiple relapses. (See
         <a class="local">
          'Remission maintenance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 2021; 73:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danieli MG, Cappelli M, Malcangi G, et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004; 63:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008; 26:S35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007; 298:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009; 23:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy 2009; 64:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Jarrousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991; 18:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004; 5:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36:1290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 2013; 43:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saech J, Owczarczyk K, Rösgen S, et al. Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 2010; 69:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011; 26:2865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umezawa N, Kohsaka H, Nanki T, et al. Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG. Mod Rheumatol 2014; 24:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigoriou A, Endean A, Sangle SR, D'Cruz DP. B cell depletion therapy and eosinophilic granulomatosis with polyangiitis with hepatic involvement. Rheumatology (Oxford) 2014; 53:1741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006; 65:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dønvik KK, Omdal R. Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int 2011; 31:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thiel J, Hässler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 2013; 15:R133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Villaescusa M, López-Montes A, López-Rubio E, et al. Treatment-resistant Churg-Strauss syndrome: progression after five years using rituximab. Nefrologia 2013; 33:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz SA, Gandino IJ, Orden AO, Allievi A. Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. Reumatol Clin 2015; 11:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 2016; 75:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanouriakis A, Kougkas N, Vassilopoulos D, et al. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Semin Arthritis Rheum 2015; 45:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emmi G, Rossi GM, Urban ML, et al. Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 2018; 77:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouldouyre MA, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009; 68:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 2019; 5:e000905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casal Moura M, Berti A, Keogh KA, et al. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. Clin Rheumatol 2020; 39:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang CR, Tsai YS, Tsai HW, Lee CH. B-Cell-Depleting Therapy Improves Myocarditis in Seronegative Eosinophilic Granulomatosis with Polyangiitis. J Clin Med 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menditto VG, Rossetti G, Olivari D, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. Rheumatology (Oxford) 2021; 60:1640.
          </a>
         </li>
         <li class="breakAll">
          U.S. Food and Drug Administration. Prescribing information for Nucala (mepolizumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125526s004lbl.pdf (Accessed on December 27, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bettiol A, Urban ML, Dagna L, et al. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis Rheumatol 2022; 74:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caminati M, Crisafulli E, Lunardi C, et al. Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. J Allergy Clin Immunol Pract 2021; 9:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akdime F, Puéchal X, Roche N. Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose? J Allergy Clin Immunol Pract 2021; 9:2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 2017; 376:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn JE, Grandpeix-Guyodo C, Marroun I, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Springer JM, Kalot MA, Husainat NM, et al. Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatol 2021; 3:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puéchal X, Pagnoux C, Baron G, et al. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. Arthritis Rheumatol 2017; 69:2175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durel CA, Berthiller J, Caboni S, et al. Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken) 2016; 68:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22:S52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assaf C, Mewis G, Orfanos CE, Geilen CC. Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. Br J Dermatol 2004; 150:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau EM, Cooper W, Bye PT, Yan K. Difficult asthma and Churg-Strauss-like syndrome: a cautionary tale. Respirology 2011; 16:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demircin G, Baysun S, Bülbül M, et al. Mycophenolate mofetil therapy in a child with Churg-Strauss syndrome. Pediatr Int 2010; 52:e164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philobos M, Perkins A, Karabayas M, et al. A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis. Rheumatol Int 2021; 41:1811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kent BD, d'Ancona G, Fernandes M, et al. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res 2020; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manka LA, Guntur VP, Denson JL, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol 2021; 126:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padoan R, Chieco Bianchi F, Marchi MR, et al. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 2020; 8:3225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppola A, Flores KR, De Filippis F. Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis. Respir Med Case Rep 2020; 30:101050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guntur VP, Manka LA, Denson JL, et al. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis. J Allergy Clin Immunol Pract 2021; 9:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jachiet M, Samson M, Cottin V, et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis Rheumatol 2016; 68:2274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol 2007; 119:1279; author reply 1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pabst S, Tiyerili V, Grohé C. Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome. Thorax 2008; 63:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Detoraki A, Di Capua L, Varricchi G, et al. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma 2016; 53:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med 2006; 355:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobell HM. Symmetry in nucleic acid structure and its role in protein-nucleic acid interactions. Annu Rev Biophys Bioeng 1976; 5:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bargagli E, Rottoli P. Omalizumab treatment associated with Churg-Strauss vasculitis. Int Arch Allergy Immunol 2008; 145:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee RU, Stevenson DD. Hydroxyurea in the treatment of Churg-Strauss syndrome. J Allergy Clin Immunol 2009; 124:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seeliger B, Förster M, Happe J, et al. Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study. J Rheumatol 2017; 44:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilos DL, Christensen J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol 1991; 88:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004; 92:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Cevallos R, Durand-Gasselin B, et al. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris) 1997; 148:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen P, Guillevin L, Baril L, et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin Exp Rheumatol 1995; 13:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 2006; 126:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishiyama A, Canalis RF. Otological manifestations of Churg-Strauss syndrome. Laryngoscope 2001; 111:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuno O, Minamoto S. Flare of eosinophilic granulomatosis with polyangiitis related to pregnancy: Case report and review of the literature. Respir Med Case Rep 2019; 26:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsurikisawa N, Oshikata C, Kinoshita A, et al. Longterm Prognosis of 121 Patients with Eosinophilic Granulomatosis with Polyangiitis in Japan. J Rheumatol 2017; 44:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saku A, Furuta S, Hiraguri M, et al. Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis. J Rheumatol 2018; 45:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldini C, Della Rossa A, Grossi S, et al. [Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre]. Reumatismo 2009; 61:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokolowska BM, Szczeklik WK, Wludarczyk AA, et al. ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center. Clin Exp Rheumatol 2014; 32:S41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groh M, Masciocco G, Kirchner E, et al. Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). J Heart Lung Transplant 2014; 33:842.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4346 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34235880" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21200183" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11318006" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8569467" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15547090" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18799051" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17684188" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25971154" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508943" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Churg-Strauss angiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17143092" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18240234" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19154547" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593229" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1676753" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14680433" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Recent progress in the pharmacotherapy of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16148732" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9448590" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11263782" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17471546" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22887848" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23590801" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19740901" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19565480" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18492710" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21325353" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24517553" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25096603" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : B cell depletion therapy and eosinophilic granulomatosis with polyangiitis with hepatic involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16531558" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Rituximab in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19789874" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Churg-Strauss syndrome successfully treated with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24286362" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24089169" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Treatment-resistant Churg-Strauss syndrome: progression after five years using rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25523986" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25467294" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25908179" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28814426" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19286908" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31245051" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31897956" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34640595" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : B-Cell-Depleting Therapy Improves Myocarditis in Seronegative Eosinophilic Granulomatosis with Polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33471122" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33471122" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34347947" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33011303" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34246444" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28514601" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21893636" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20513524" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20109753" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Sustained response to mepolizumab in refractory Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16052573" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33512787" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263885" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28678392" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26315340" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9735064" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Interferon-alpha treatment of four patients with the Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19109574" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15675136" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15030353" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Churg-Strauss syndrome: successful treatment with mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21504509" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Difficult asthma and Churg-Strauss-like syndrome: a cautionary tale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20723119" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Mycophenolate mofetil therapy in a child with Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34350491" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31984211" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33548468" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32505716" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32300522" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33065367" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26946346" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17349685" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18663073" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26377630" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16990394" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Omalizumab for asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/182065" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Symmetry in nucleic acid structure and its role in protein-nucleic acid interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17921677" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Omalizumab treatment associated with Churg-Strauss vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19703710" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hydroxyurea in the treatment of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28412705" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Interferon-αfor Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1955642" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14756469" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9255326" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7656465" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16377381" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16698700" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Ear, nose and throat manifestations of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568616" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Otological manifestations of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30456168" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Flare of eosinophilic granulomatosis with polyangiitis related to pregnancy: Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28572468" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Longterm Prognosis of 121 Patients with Eosinophilic Granulomatosis with Polyangiitis in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9990352" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12967693" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29907668" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19633798" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : [Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24854371" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24709271" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
